title: Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.
abstract: To discuss the mechanism and clinical application of EGFR-TKI and ALK/ROS1 inhibitors in non-small cell lung cancer (NSCLC), we reviewed recent available data mainly from PubMed. We found that chemotherapy, progression-free survival (PFS), objective response rate (ORR), and quality of life of patients with advanced NSCLC can be greatly improved in these drugs medication compared with conventional chemotherapy. Though many questions like resistance to EGFR-TKI and ALK/ROS1 inhibitors exist, molecular targeted therapy is an important therapeutic method for the management of NSCLC. The role of molecule targeted therapy in the initiation and development of NSCLC deserves further study.
authors.affiliation: Department of Cardiovascular Medicine, Xiangya Hospital, Central South University Changsha 410008, Hunan, China ; Department of Cardiovascular Medicine, The first people's hospital of Changde city Changde 415000, Hunan, China.
authors.forename: Liangqing
authors.initials: L
authors.lastname: Ge
authors.affiliation: Department of Cardiovascular Medicine, Xiangya Hospital, Central South University Changsha 410008, Hunan, China.
authors.forename: Ruizheng
authors.initials: R
authors.lastname: Shi
keywords: ALK/ROS1 inhibitors; EGFR-TKI inhibitors; non-small cell lung cancer